I. Introduction
Parkinson’s disease (PD) is a neurodegenerative condition marked by the death of dopaminergic neurons in the substantia nigra. This results in motor symptoms that are responsive to dopaminergic medications, such as bradykinesia, tremor, and stiffness. Cognitive impairment in PD progresses at different rates, with some patients developing dementia, impacting daily living activities [1]. Non-motor symptoms in PD, including sensory, autonomic, cognitive-behavioural, and sleep-related issues, significantly affect patients’ health and quality of life [2]. The World Health Organization (WHO) emphasizes recognizing and addressing these non-motor symptoms to improve patient care. Mild Cognitive Impairment (MCI) in PD presents challenges in diagnosis and treatment due to the lack of disease-modifying therapies.